{"id":5645,"date":"2024-06-13T16:32:04","date_gmt":"2024-06-13T16:32:04","guid":{"rendered":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/?p=5645"},"modified":"2024-06-14T01:08:13","modified_gmt":"2024-06-14T01:08:13","slug":"frost","status":"publish","type":"post","link":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/frost\/","title":{"rendered":"Simon Frost"},"content":{"rendered":"<p><img decoding=\"async\" class=\"lazyload alignnone size-full wp-image-5646\" src=\"http:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Simon-Frost.png\" data-orig-src=\"http:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Simon-Frost.png\" alt=\"\" width=\"300\" height=\"300\" srcset=\"data:image\/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27300%27%20height%3D%27300%27%20viewBox%3D%270%200%20300%20300%27%3E%3Crect%20width%3D%27300%27%20height%3D%27300%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E\" data-srcset=\"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Simon-Frost-66x66.png 66w, https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Simon-Frost-150x150.png 150w, https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Simon-Frost-200x200.png 200w, https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Simon-Frost.png 300w\" data-sizes=\"auto\" data-orig-sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>Simon Frost is the CEO of Tiber Capital Group, an investment company that operates large portfolios of single-family homes.\u00a0 In 2017 his daughter Annabel was diagnosed with an ultra-rare neurological disease, Alternating Hemiplegia of Childhood, and since then he has dedicated much of his time to advancements in rare disease research and therapies.\u00a0 Simon now serves on the boards of several organizations, including RARE-X, Global Genes, Uncommon Cures, the Cures Acceleration Network Review Board at the NIH, Cure AHC, Hope For Annabel, and the Genomic Answers for Children\u2019s Health Alliance.\u00a0\u00a0 Simon earned bachelor&#8217;s and master&#8217;s degrees in economics from Cambridge University and a bachelor&#8217;s degree in finance from the University of South Africa.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Frost is the CEO of Tiber Capital Group, an investment company that operates large portfolios of single-family homes.\u00a0 In 2017 his daughter Annabel was diagnosed with an ultra-rare neurological disease, Alternating Hemiplegia of Childhood, and since then he has dedicated much of his time to advancements in rare disease research and therapies.\u00a0 Simon now<\/p>\n","protected":false},"author":6,"featured_media":5646,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"class_list":["post-5645","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-creative"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.1.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Simon Frost is the CEO of Tiber Capital Group, an investment company that operates large portfolios of single-family homes. In 2017 his daughter Annabel was diagnosed with an ultra-rare neurological disease, Alternating Hemiplegia of Childhood, and since then he has dedicated much of his time to advancements in rare disease research and therapies. Simon now\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"mkavounis\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/frost\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.1.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"NINDS Genetic Strategies to Treat the Epilepsies -\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Simon Frost - NINDS Genetic Strategies to Treat the Epilepsies\" \/>\n\t\t<meta property=\"og:description\" content=\"Simon Frost is the CEO of Tiber Capital Group, an investment company that operates large portfolios of single-family homes. In 2017 his daughter Annabel was diagnosed with an ultra-rare neurological disease, Alternating Hemiplegia of Childhood, and since then he has dedicated much of his time to advancements in rare disease research and therapies. Simon now\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/frost\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2024-06-13T16:32:04+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2024-06-14T01:08:13+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Simon Frost - NINDS Genetic Strategies to Treat the Epilepsies\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Simon Frost is the CEO of Tiber Capital Group, an investment company that operates large portfolios of single-family homes. In 2017 his daughter Annabel was diagnosed with an ultra-rare neurological disease, Alternating Hemiplegia of Childhood, and since then he has dedicated much of his time to advancements in rare disease research and therapies. Simon now\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/2024\\\/06\\\/13\\\/frost\\\/#blogposting\",\"name\":\"Simon Frost - NINDS Genetic Strategies to Treat the Epilepsies\",\"headline\":\"Simon Frost\",\"author\":{\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/author\\\/mkavounis\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/wp-content\\\/uploads\\\/sites\\\/91\\\/2024\\\/06\\\/Simon-Frost.png\",\"width\":300,\"height\":300},\"datePublished\":\"2024-06-13T16:32:04+00:00\",\"dateModified\":\"2024-06-14T01:08:13+00:00\",\"inLanguage\":\"en-US\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/2024\\\/06\\\/13\\\/frost\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/2024\\\/06\\\/13\\\/frost\\\/#webpage\"},\"articleSection\":\"Creative\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/2024\\\/06\\\/13\\\/frost\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/category\\\/creative\\\/#listItem\",\"name\":\"Creative\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/category\\\/creative\\\/#listItem\",\"position\":2,\"name\":\"Creative\",\"item\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/category\\\/creative\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/2024\\\/06\\\/13\\\/frost\\\/#listItem\",\"name\":\"Simon Frost\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/2024\\\/06\\\/13\\\/frost\\\/#listItem\",\"position\":3,\"name\":\"Simon Frost\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/category\\\/creative\\\/#listItem\",\"name\":\"Creative\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/#organization\",\"name\":\"Symposium for Promoting the Advancement of Research Knowledge in ME\\\/CFS (SPARKME)\",\"url\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/author\\\/mkavounis\\\/#author\",\"url\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/author\\\/mkavounis\\\/\",\"name\":\"mkavounis\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/2024\\\/06\\\/13\\\/frost\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/78999b25f9750bfe24c485d98fc21efbd175a28006611d732e517a5d6e52275c?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"mkavounis\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/2024\\\/06\\\/13\\\/frost\\\/#webpage\",\"url\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/2024\\\/06\\\/13\\\/frost\\\/\",\"name\":\"Simon Frost - NINDS Genetic Strategies to Treat the Epilepsies\",\"description\":\"Simon Frost is the CEO of Tiber Capital Group, an investment company that operates large portfolios of single-family homes. In 2017 his daughter Annabel was diagnosed with an ultra-rare neurological disease, Alternating Hemiplegia of Childhood, and since then he has dedicated much of his time to advancements in rare disease research and therapies. Simon now\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/2024\\\/06\\\/13\\\/frost\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/author\\\/mkavounis\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/author\\\/mkavounis\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/wp-content\\\/uploads\\\/sites\\\/91\\\/2024\\\/06\\\/Simon-Frost.png\",\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/2024\\\/06\\\/13\\\/frost\\\/#mainImage\",\"width\":300,\"height\":300},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/2024\\\/06\\\/13\\\/frost\\\/#mainImage\"},\"datePublished\":\"2024-06-13T16:32:04+00:00\",\"dateModified\":\"2024-06-14T01:08:13+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/#website\",\"url\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/\",\"name\":\"Symposium for Promoting the Advancement of Research Knowledge in ME\\\/CFS (SPARKME)\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/event.roseliassociates.com\\\/ninds-genetic-strategies\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Simon Frost - NINDS Genetic Strategies to Treat the Epilepsies","description":"Simon Frost is the CEO of Tiber Capital Group, an investment company that operates large portfolios of single-family homes. In 2017 his daughter Annabel was diagnosed with an ultra-rare neurological disease, Alternating Hemiplegia of Childhood, and since then he has dedicated much of his time to advancements in rare disease research and therapies. Simon now","canonical_url":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/frost\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/frost\/#blogposting","name":"Simon Frost - NINDS Genetic Strategies to Treat the Epilepsies","headline":"Simon Frost","author":{"@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/author\/mkavounis\/#author"},"publisher":{"@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Simon-Frost.png","width":300,"height":300},"datePublished":"2024-06-13T16:32:04+00:00","dateModified":"2024-06-14T01:08:13+00:00","inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/frost\/#webpage"},"isPartOf":{"@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/frost\/#webpage"},"articleSection":"Creative"},{"@type":"BreadcrumbList","@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/frost\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies#listItem","position":1,"name":"Home","item":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies","nextItem":{"@type":"ListItem","@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/category\/creative\/#listItem","name":"Creative"}},{"@type":"ListItem","@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/category\/creative\/#listItem","position":2,"name":"Creative","item":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/category\/creative\/","nextItem":{"@type":"ListItem","@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/frost\/#listItem","name":"Simon Frost"},"previousItem":{"@type":"ListItem","@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/frost\/#listItem","position":3,"name":"Simon Frost","previousItem":{"@type":"ListItem","@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/category\/creative\/#listItem","name":"Creative"}}]},{"@type":"Organization","@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/#organization","name":"Symposium for Promoting the Advancement of Research Knowledge in ME\/CFS (SPARKME)","url":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/"},{"@type":"Person","@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/author\/mkavounis\/#author","url":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/author\/mkavounis\/","name":"mkavounis","image":{"@type":"ImageObject","@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/frost\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/78999b25f9750bfe24c485d98fc21efbd175a28006611d732e517a5d6e52275c?s=96&d=mm&r=g","width":96,"height":96,"caption":"mkavounis"}},{"@type":"WebPage","@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/frost\/#webpage","url":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/frost\/","name":"Simon Frost - NINDS Genetic Strategies to Treat the Epilepsies","description":"Simon Frost is the CEO of Tiber Capital Group, an investment company that operates large portfolios of single-family homes. In 2017 his daughter Annabel was diagnosed with an ultra-rare neurological disease, Alternating Hemiplegia of Childhood, and since then he has dedicated much of his time to advancements in rare disease research and therapies. Simon now","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/#website"},"breadcrumb":{"@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/frost\/#breadcrumblist"},"author":{"@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/author\/mkavounis\/#author"},"creator":{"@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/author\/mkavounis\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Simon-Frost.png","@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/frost\/#mainImage","width":300,"height":300},"primaryImageOfPage":{"@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/frost\/#mainImage"},"datePublished":"2024-06-13T16:32:04+00:00","dateModified":"2024-06-14T01:08:13+00:00"},{"@type":"WebSite","@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/#website","url":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/","name":"Symposium for Promoting the Advancement of Research Knowledge in ME\/CFS (SPARKME)","inLanguage":"en-US","publisher":{"@id":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/#organization"}}]},"og:locale":"en_US","og:site_name":"NINDS Genetic Strategies to Treat the Epilepsies -","og:type":"article","og:title":"Simon Frost - NINDS Genetic Strategies to Treat the Epilepsies","og:description":"Simon Frost is the CEO of Tiber Capital Group, an investment company that operates large portfolios of single-family homes. In 2017 his daughter Annabel was diagnosed with an ultra-rare neurological disease, Alternating Hemiplegia of Childhood, and since then he has dedicated much of his time to advancements in rare disease research and therapies. Simon now","og:url":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/frost\/","article:published_time":"2024-06-13T16:32:04+00:00","article:modified_time":"2024-06-14T01:08:13+00:00","twitter:card":"summary_large_image","twitter:title":"Simon Frost - NINDS Genetic Strategies to Treat the Epilepsies","twitter:description":"Simon Frost is the CEO of Tiber Capital Group, an investment company that operates large portfolios of single-family homes. In 2017 his daughter Annabel was diagnosed with an ultra-rare neurological disease, Alternating Hemiplegia of Childhood, and since then he has dedicated much of his time to advancements in rare disease research and therapies. Simon now"},"aioseo_meta_data":{"post_id":"5645","title":null,"description":null,"keywords":[],"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":[],"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"BlogPosting","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2024-06-13 16:32:04","updated":"2025-07-23 20:34:15","focus_keyword":null,"additional_keywords":null,"truseo_locale":null,"seo_analyzer_scan_date":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/category\/creative\/\" title=\"Creative\">Creative<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tSimon Frost\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies"},{"label":"Creative","link":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/category\/creative\/"},{"label":"Simon Frost","link":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/frost\/"}],"_links":{"self":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts\/5645","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/comments?post=5645"}],"version-history":[{"count":1,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts\/5645\/revisions"}],"predecessor-version":[{"id":5647,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts\/5645\/revisions\/5647"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/media\/5646"}],"wp:attachment":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/media?parent=5645"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/categories?post=5645"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/tags?post=5645"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}